CASP1 and diabetic kidney disease: Lowering NLRP3 levels, demonstrated in numerous studies to mitigate renal inflammation and improve DKD, is currently critical for therapeutic intervention targeting the TXNIP/NLRP3/caspase-1/GSDMD pathway.